ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registries"

  • Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium

    The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

    Mary Beth Son1, Yukiko Kimura 2, Kristiina Aalto 3, Lillemor Berntson 4, Johnathan Dallas 1, Ciaran Duffy 5, Mia Glerup 6, Jaime Guzman 7, Troels Herlin 8, Petteri Hovi 9, Kimme Hyrich 10, Jens Klotsche 11, Bo Magnusson 12, Vanessa McIntyre 13, Ellen Nordal 14, Seza Ozen 15, Maria Jose Santos 16, Betul Sozeri 17 and Timothy Beukelman 18, 1Boston Children's Hospital, Boston, Massachusetts, 2Hackensack Meridian School of Medicine, Hackensack, 3Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 4Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 5Ottawa, Canada, 6Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 7University of British Columbia and BC Children's Hospital, Vancouver, Canada, 8Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, 9Helsinki University Hospital, Helsinki, Finland, 10Manchester, United Kingdom, 11Berlin, Germany, 12Karolinska University Hospital, Stockholm, Sweden, 13Manchester University, Manchester UK, United Kingdom, 14Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 15Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, 16Portugal, 17Boston, Turkey, 18University of Alabama at Birmingham, Birmingham

    Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
  • Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium

    Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years

    Jessica Neely1, Adam Huber 2 and Susan Kim 3 for the CARRA investigators, 1University of California, San Francisco, San Francisco, California, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3University of California, San Francisco, San Francisco

    Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
  • Abstract Number: 1813 • 2019 ACR/ARP Annual Meeting

    New Medications Are Needed for Children with Juvenile Idiopathic Arthritis

    Hermine Brunner1, Laura Schanberg 2, Yukiko Kimura 3, Anne Dennos 4, Guy Eakin 5, Dominic Co 6, Robert Colbert 7, Robert Fuhlbrigge 8, Ellen Goldmuntz 9, Daniel Kingsbury 10, Sandra Mintz 11, Karen Onel 12, Cathy Patty-Resk 13, Lisa G. Rider 14, Rayfel Schneider 15, Allen Watts 16, Emily von-Scheven 17, Daniel J. Lovell 18, Timothy Beukelman 19 and for PRCSG Advisory Council and CARRA Registry Investigators 20, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Duke University Medical Center, Durham, NC, 3Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, 4Duke Clinical Research Institute, Durham, NC, 5Arthritis Foundation, Atlanta, 6of Wisconsin School of Medicine and Public Health, Madison, WI, 7Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, 8Department of Rheumatology, Children’s Hospital Colorado, Denver, CO, 9NIAID, Washingto, DC, 10LHS Pediatrics, Prtland, OR, 11Children's Hospital of Los Angeles, Los Angeles, CA, 12Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, NY, 13Children's Hospital of Michigan, Detroit, MI, 14Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD, 15Hospital for Sick Children, Toronto, ON, Canada, 16Cincinnati Children's Hospital MEdical Center, Cincinnati, OH, 17University of California San Francisco, San Francisco, 18Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 19University of Alabama Birmingham, Birmingham, AL, 20Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH

    Background/Purpose: Existing legislation in the United States (US) promotes the study of new medications in children.  Biologic disease-modifying-drugs (bDMARDs) and small molecules proven effective and…
  • Abstract Number: 1420 • 2019 ACR/ARP Annual Meeting

    Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)

    Kim Lauper1, Denis Mongin 2, Sytske Anne Bergstra 3, Denis Choquette 4, Catalin Codreanu 5, Ori Elkayam 6, Kimme Hyrich 7, Florenzo Iannone 8, Eirik Kristianslund 9, Tore Kvien 10, Burkhard Leeb 11, Galina Lukina 12, Dan Nordström 13, Fatos Onen 14, Karel Pavelka 15, Manuel Pombo-Suarez 16, Ziga Rotar 17, Maria José Santos 18, Anja Strangfeld 19, Delphine Courvoisier 20 and Axel Finckh 20, 1Division of Rheumatology, Geneva University Hospital, Switzerland / Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Geneva, Switzerland, 2Division of Rheumatology, Geneva University Hospitals, Switzerland, Geneva, Switzerland, 3Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 4Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, 5Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 6Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, 7Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom / NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, 8Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 9Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 10Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 11Second Department of Medicine, Centre for Rheumatology Lower Austria, State Hospital Stockerau, Stockerau, Austria., Stockerau, Austria, 12V.A.Nasonova Research Institute of Rheumatology, Moscow, Russian Federation., Moscow, Russia, 13Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 14Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 15Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 16Rheumatology Service , Hospital Clinico Universitario , Santiago de Compostela , Spain., Santiago de Compostela, Spain, 17UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 18Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 19German Rheumatism Research Center (DRFZ), Berlin, Germany, 20Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland

    Background/Purpose: In many countries, JAK-inhibitors (JAKi) have been recently accepted for the treatment of patients with rheumatoid arthritis (RA). However, prescription patterns may differ notably…
  • Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting

    Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar

    Lisa Baganz1, Yvette Meißner1, Perter Herzer2, Jürgen Braun3, Anett Gräßler4, Anja Strangfeld5 and Angela Zink6, 1Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, 2Scientific Advisory Board, Munich, Germany, 3Ruhr-University Bochum, Bochum, Germany, 4Rheumatologist, Pirna, Germany, 5Epidemiology, German Rheumatism Research Center, Berlin, Germany, 6Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany

    Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
  • Abstract Number: 1089 • 2017 ACR/ARHP Annual Meeting

    Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry

    Gabriela Schmajuk1, Michael Evans2, Julia Kay3 and Jinoos Yazdany4, 1San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 2University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Tuberculosis (TB) testing prior to biologic DMARD use helps prevent potentially fatal, medication-related adverse events and is a National Quality Forum-endorsed quality measure. We…
  • Abstract Number: 991 • 2016 ACR/ARHP Annual Meeting

    Familial Aggregation of Rheumatoid Arthritis in Sarcoidosis: A Register-Based Case-Control Study in Sweden

    Elizabeth V. Arkema, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Sarcoidosis is an inflammatory disease with unknown etiology that primarily affects the lungs and lymph glands. Sarcoidosis shares some features with rheumatoid arthritis (RA),…
  • Abstract Number: 1614 • 2016 ACR/ARHP Annual Meeting

    Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Alain Saraux9, Thierry Schaeverbeke10, Jean Sibilia11, Martin Soubrier12, Olivier Vittecoq13, Elodie Perrodeau14, Philippe Ravaud15, Xavier Mariette16 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Rheumatology, Paris Descartes University, Paris, France, 8Rheumatology, University Hospital, Lille, France, 9Rheumatology, Brest University Hospital, Brest, France, 10Rheumatology, CHU Bordeaux, Bordeaux, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 13Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 14Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 15Epidemiologist, PARIS, France, 16Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Background/Purpose: Data are very limited concerning the association between cotreatment with a conventional synthetic DMARD (csDMARD) and long term retention of abatacept (ABA), rituximab (RTX) and tocilizumab…
  • Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting

    Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Alain Saraux9, Thierry Schaeverbeke10, Jean Sibilia11, Martin Soubrier12, Olivier Vittecoq13,14, Elodie Perrodeau15, Philippe Ravaud16, Xavier Mariette17 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Rheumatology, Paris Descartes University, Paris, France, 8Rheumatology, University Hospital, Lille, France, 9Rheumatology, Brest University Hospital, Brest, France, 10Rheumatology, CHU Bordeaux, Bordeaux, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 13Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 14Rheumatology, Rouen University Hospital, Rouen, France, 15Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 16Epidemiologist, PARIS, France, 17Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…
  • Abstract Number: 2540 • 2016 ACR/ARHP Annual Meeting

    The Longitudinal Impact of Biologic Use on Disability within a RA Registry

    N A Shadick1, Nicole Gerlanc2, M Frits1, Bradley S. Stolshek3, Brenna Brady2, Christine Iannaccone4, David Collier5, Jing Cui6, Alex Mutebi7 and Michael Weinblatt4, 1Brigham and Women's Hospital, Boston, MA, 2Health Analytics, LLC, Columbia, MD, 3Amgen, Thousand Oaks, CA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Amgen Inc., Thousand Oaks, CA, 6Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Global Health Economics, Amgen, Thousand Oaks, CA

    Background/Purpose: Biologics have become the standard of care for treating moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to small molecule…
  • Abstract Number: 2614 • 2016 ACR/ARHP Annual Meeting

    Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Jacques Morel2,3, Arnaud Constantin4, Thomas Bardin5, Alain Cantagrel6,7, Bernard Combe8, Maxime Dougados9,10, Rene-Marc Flipo11, Alain Saraux12, Thierry Schaeverbeke13, Jean Sibilia14, Martin Soubrier15, Olivier Vittecoq16, Elodie Perrodeau17, Philippe Ravaud18, Xavier Mariette19 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Immuno-Rheumatology, University Hospital of Lapeyronie, University Montpellier 1, Montpellier, France, 4Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 5Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisière, Paris, France, 6Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 7Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, 8Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 9Rheumatology, Paris Descartes University, Paris, France, 10René Descartes University and Hôpital Cochin, Paris, France, 11Rheumatology, Hopital R Salengro CHRU, Lille, France, 12Rheumatology, Brest University Hospital, Brest, France, 13Rheumatology, CHU Bordeaux, Bordeaux, France, 14Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 15Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 16Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 17Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 18Epidemiology, Hotel Dieu, PARIS, France, 19Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Background/Purpose: Assessment of safety in randomized controlled trials is limited by trial durations, and selection of patients with few or now comorbidities. Such limitations can…
  • Abstract Number: 565 • 2015 ACR/ARHP Annual Meeting

    Factors Associated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry

    Leslie Harrold1,2, Ani John3, George W. Reed1, Chitra Karki2, Robert Magner1, Joel M. Kremer4, Ashwini Shewede3 and Jeffrey Greenberg2,5, 1University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5NYU School of Medicine, New York, NY

    Background/Purpose: The goal of treatment for patients with rheumatoid arthritis (RA) is to achieve and maintain low disease activity (LDA) or remission. Little information is…
  • Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting

    Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry

    Dimitrios A. Pappas1,2, Ani John3, Carol J. Etzel2,4, Chitra Karki2, YouFu Li5, Joel M. Kremer6, Tmirah Haselkorn3 and Jeffrey D. Greenberg2,7, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc, South San Francisco, CA, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5University of Massachusetts Medical School, Worcester, MA, 6Albany Medical College and The Center for Rheumatology, Albany, NY, 7NYU School of Medicine, New York, NY

    Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…
  • Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting

    Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry

    Leslie Harrold1,2, Ani John3, George W. Reed2,4, Chitra Karki2, YouFu Li4, Joel M. Kremer5, Tmirah Haselkorn6 and Jeffrey D. Greenberg2,7, 1Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4University of Massachusetts Medical School, Worcester, MA, 5Albany Medical College, Albany, NY, 6Genentech, Inc, South San Francisco, CA, 7NYU School of Medicine, New York, NY

    Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…
  • Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting

    Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry

    Leslie Harrold1,2, Ani John3, George W. Reed1,4, Chitra Karki1, YouFu Li4, Joel Kremer5, Tmirah Haselkorn6 and Jeffrey D. Greenberg1,7, 1Corrona, LLC, Southborough, MA, 2Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, 3Genentech, Inc., South San Francisco, CA, 4University of Massachusetts Medical School, Worcester, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6Genentech, Inc, South San Francisco, CA, 7NYU School of Medicine, New York, NY

    Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology